Medical Beauty · Diagnostic
Japanese Patient Acquisition, diagnose before entering the competition
Market growth does not establish provider-level profitability. RIVACTA's Medical Beauty Diagnostic evaluates Japanese-language consultation, booking, aftercare, regulatory readiness, and contribution-margin conditions.
The real challenge
Why Japanese patient acquisition is hard
Without validating clinical fit, consultation, and aftercare capacity, price competition and referral-only acquisition make profitability difficult to assess.
You're signing contracts without understanding legal fee caps (clinic 30%, hospital 20%, tertiary 15%) and the cost structure.
Marketing execution is delayed because regulatory readiness — medical ad pre-review, Medical Care Act, privacy requirements — isn't in place.
RIVACTA's approach
Diagnose regulation and differentiation before executing
RIVACTA's Medical Beauty Diagnostic evaluates demand in the international patient market, referral fee and contract structures, medical advertising regulatory readiness, and clinic-specific differentiation strategy to propose a safe, sustainable acquisition roadmap.
- Japanese patient segment analysis within the international patient market (2.01M in 2025, +71% YoY)
- Referral fee legal caps and contract structure appropriateness
- Readiness assessment for medical ad pre-review, Medical Care Act, and privacy compliance
- Differentiation points and channel priorities in an oversupplied market
Market evidence data